Version history

{
  "session_id": "sess-hyp-f093318d54c9",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "llm",
  "action": "support",
  "content": "\n\n# Expert Assessment: Liquid-to-Solid Phase Transition Pathology in RNP Granules\n\n## Overall Confidence Score: 0.78\n\n---\n\n## Executive Summary\n\nThis hypothesis presents a mechanistically compelling framework with substantial experimental support. The dual-scaffold model (TIA1/G3BP1) modulating client protein behavior (TDP-43/FUS) explains selective neuronal vulnerability with high plausibility. However, significant translational gaps exist, particularly in target druggability and therapeutic window definition. **The primary translational risk is that TDP-43 and FUS are essential proteins—therapeutic modulation carries substantial safety liability.**\n\n---\n\n## 1. Target Druggability Assessment\n\n| Target | Druggability | Confidence | Key Considerations |\n|--------|-------------|------------|-------------------|\n| **TDP-43** | Moderate-High | 0.75 | Intrinsically disordered region (IDR) challenging for small molecules; ASO approaches feasible; aggregation nucleation site potentially targetable |\n| **FUS** | Moderate | 0.68 | Similar IDR challenges; nuclear localization sequence (NLS) offers targeting opportunity; loss-of-function toxic in non-motor neurons |\n| **TIA1** | Moderate | 0.72 | Upstream of client proteins; prion-like domain structure more defined; phosphorylation sites provide modifiable PTM nodes |\n| **G3BP1** | Low-Moderate | 0.60 | Limited structural data; NTF2-like domain",
  "tokens_used": "351",
  "persona_id": "persona-domain_expert"
}